Human respiratory syncytial virus (RSV) (A2) Fusion glycoprotein / RSV-F Insect Cell Lysate (WB positive control): Product Information
This RSV RSV Fusion overexpression lysate was created in Baculovirus-Insect cells and intented for use as a Western blot (WB) positive control. Purification of RSV Fusion protein (Cat: 11049-V08B) from the overexpression lysate was verified.
A DNA sequence encoding the extracellular domain of human RSV Fusion glycoprotein (P03420.1) (Met 1-Thr 529) was expressed, fused with a polyhistidine tag at the C-terminus.
The secreted recombinant human RSV-F comprises 518 amino acids with a predicted molecular mass of 58 kDa. The RSV F0 precursor protein is cleaved into the disulfide-linked F1 and F2 subunits. As a result of glycosylation, the apparent molecular mass of the protein is approximately 45-55 kDa and 18 kDa in SDS-PAGE under reducing conditions, corresponding to the two subunits respectively.
Cell lysate was prepared by homogenization of the over-expressed cells in ice-cold modified RIPA Lysis Buffer with cocktail of protease inhibitors (Sigma). Cell debris was removed by centrifugation. Protein concentration was determined by Bradford assay (Bio-Rad protein assay, Microplate Standard assay). The cell lysate was boiled for 5 min in 1 x SDS loading buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% b-mercaptoethanol, and lyophilized.
1. Centrifuge the tube for a few seconds and ensure the pellet at the bottom of the tube.
2. Re-dissolve the pellet using 200μL pure water and boil for 2-5 min.
1 X Sample Buffer (1 X modified RIPA buffer+1 X SDS loading buffer).
Stability & Storage
Store at 4℃ for up to twelve months from date of receipt. After re-dissolution, aliquot and store at -80℃ for up to twelve months. Avoid repeated freeze-thaw cycles.
Western Blot (WB) Optimal dilutions/concentrations should be determined by the end user.
Human respiratory syncytial virus (RSV) (A2) Fusion glycoprotein / RSV-F Insect Cell Lysate (WB positive control): Alternative Names
RSV F Overexpression Lysate; RSV HRSVgp08 Overexpression Lysate
RSV Fusion Background Information
Human respiratory syncytial virus (HRSV) is the most common etiological agent of acute lower respiratory tract disease in infants and can cause repeated infections throughout life. It is classified within the genus pneumovirus of the family paramyxoviridae. Like other members of the family, HRSV has two major surface glycoproteins (G and F) that play important roles in the initial stages of the infectious cycle. The G protein mediates attachment of the virus to cell surface receptors, while the F protein promotes fusion of the viral and cellular membranes, allowing entry of the virus ribonucleoprotein into the cell cytoplasm. The fusion (F) protein of RSV is synthesized as a nonfusogenic precursor protein (F), which during its migration to the cell surface is activated by cleavage into the disulfide-linked F1 and F2 subunits. This fusion is pH independent and occurs directly at the outer cell membrane, and the F2 subunit was identifed as the major determinant of RSV host cell specificity. The trimer of F1-F2 interacts with glycoprotein G at the virion surface. Upon binding of G to heparan sulfate, the hydrophobic fusion peptide is unmasked and induces the fusion between host cell and virion membranes. Notably, RSV fusion protein is unique in that it is able to interact directly with heparan sulfate and therefore is sufficient for virus infection. Furthermore, the fusion protein is also able to trigger p53-dependent apoptosis.
Martin-Gallardo A. et al., 1993, J Gen Virol. 74 (3): 453-8.
Jose A M. et al., 1997, J Gen Virol. 78: 2411-8.
Feldman SA. et al., 1999, J Virol. 73 (8): 6610-7.
Zlateva K.T. et al., 2004, J Virol. 78 (9): 4675-83.
Trento A. et al., 2006, J Virol. 80 (2): 975-84.
Branigan P J. et al., 2006, J Gen Virol. 87 (2): 395-8.
Eckardt-Michel J. et al., 2008, J. Virol. 82: 3236-49.
Successfully added to cart Please enter catalog numberSubmitted successfullyNetwork ErrorPlease enter your company namePlease enter your namePlease enter your emailPlease enter a valid email addressPlease enter some messageNot found.